文献速递治疗药物监测与药物基因组学肝肾功能剂量调整

CYP3A5基因导向他克莫司剂量与传统剂量在肾移植中的比较

Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-03

该随机对照研究比较肾移植患者传统他克莫司剂量(0.1 mg/kg/天)与CYP3A5基因导向剂量(*1/*1、*1/*3、*3/*3分别0.125、0.1、0.08 mg/kg/天,初始3天)的疗效。中位37个月随访肾小球滤过率及移植物/患者生存无显著差异。

要点

  • 基因导向组第3天他克莫司治疗浓度达标率显著更高。
  • CYP3A5*3/*3基因型中基因导向组超治疗浓度比例更低。
  • 基因导向组DGF发生率更高,尤其CYP3A5*1/*1者需密切监测。

核心结论

  • CYP3A5基因导向剂量可提高他克莫司治疗浓度达标率。
  • CYP3A5*1/*1且DGF高风险患者应密切监测,因高剂量他克莫司增加DGF和降低肾小球滤过率风险。

研究设计与样本

  • 随机对照研究,比较传统剂量组63例与基因导向剂量组62例肾移植患者。
  • 传统组他克莫司剂量0.1 mg/kg/天;基因导向组初始3天按CYP3A5*1/*1、*1/*3、*3/*3分别给0.125、0.1、0.08 mg/kg/天,之后两组均调整剂量至治疗浓度。

主要发现

  • 中位37个月随访肾小球滤过率、移植物生存及患者生存无显著差异。

临床怎么用

  • 可依据CYP3A5基因型调整肾移植术后初始他克莫司剂量以提高早期治疗浓度达标率。
  • 对CYP3A5*1/*1且DGF高风险患者应密切监测DGF和肾功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Although cytochromeP450(CYP)3A5 gene polymorphism affects personalized tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be determined to adjust the doses. The aims were to compare the therapeutic ranges and clinical outcomes between the conventional and genotype-guided tacrolimus doses. METHODS: This randomized controlled study compared 63 cases of the conventional tacrolimus dose group (0.1 mg/kg/day) with 62 cases of the genotype-guided doses group of 0.125, 0.1 and 0.08 mg/kg for CYP3A5*1/*1, *1/*3, and *3/*3 genotypes for the initial 3 days of kidney transplantation. After day 3, dose adjustment occurred in both groups to achieve therapeutic concentrations. RESULTS: The genotype-guided group had an increased proportion of patients with tacrolimus concentrations in the therapeutic range at the steady state on day 3 (40.3 vs 23.8%, P = .048). A lower proportion of over-therapeutic concentration patients was noted in the genotype-guided group in the CYP3A5*3/*3 genotype (9.7 vs 27%, P = .013). Unexpectedly, more delayed graft functions (DGFs) were in the genotype-guided group (41.9 vs 22.2%, P = .018) especially in the CYP3A5*1/*1 participants who might have had an aggravated DGF by a longer ischaemic time and higher serum donor creatinine levels than in the control group. There were no significant differences of glomerular filtration rates or graft or patient survivals over a median 37-month follow-up period. CONCLUSIONS: Determination of the CYP3A5 genotype improved therapeutic range achievement. CYP3A5*1/*1 patients who have high risks of DGF should be closely monitored because of an increased risk of DGF and reduced glomerular filtration rate with high tacrolimus doses.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Anutrakulchai S, Pongskul C, Kritmetapak K, et al. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients. Br J Clin Pharmacol. 2019. PMID: 31077425. doi:10.1111/bcp.13980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。